Abstract: The present invention relates to compounds which are intermediates in the synthesis of bile acid derivatives with pharmacological activity. The invention relates to compounds of general formula (I): wherein: , R1, R2, R3, R4, R5, R6 and Y are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids which are useful in the treatment of conditions such as liver disease. In addition, the invention relates to a method of synthesizing these intermediates and a method of preparing obeticholic acid and obeticholic acid analogues from the compounds of the invention.

Abstract: Provided herein are methods of processing a fluid that include the use of one or both of a circuit system including a tangential flow filtration (TFF) unit and a circuit system including a tangential flow virus filtration (TFVF) unit. Also provided are integrated and continuous processes for manufacturing a therapeutic protein drug substance that include a step of processing a fluid including the recombinant therapeutic protein using any of the methods provided herein.

Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.

Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.

Abstract: In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelope selections from individual CH505, and methods for swarm immunizations using combinations of HIV-1 envelopes.

Abstract: A novel optogenetic system, including constructs and methods, is provided based on the interaction of Rhodopseudomonas palustris BphP1 and Rhodopseudomonas palustris PpsR2 or a non-dimerizing variant thereof.

Abstract: The disclosure provides novel programmable targeting sequences and applications thereof. The targeting sequences can be engineered for binding to proteins, polypeptides, and other macromolecules.

Abstract: The present invention provides S. suis strains that elicit an immune response in animal S. suis, compositions comprising said strains, methods of vaccination against S. suis, and kits for use with such methods and compositions. The invention further provides a comprehensive, unambiguous method of capsular typing based on whole genome sequencing and bioinformatics. This capsular typing approach can accurately identify serotypes even when strains possess novel capsular loci and can be used to determine which strains to include when formulating vaccines, including herd specific vaccines.

Abstract: Disclosed herein are mutant photosynthetic microorgnaisms having an attenuated SGI1 gene. The mutants have reduced chlorophyll and increased productivity with respect to wild type cells. Also disclosed are methods of using such mutants for producing biomass or bioproducts, and methods of screening for such mutants.

Abstract: Disclosed here are compositions comprising a curcuminoid-peptide complex. Also disclosed are methods of preparing a curcuminoid-peptide complex, comprising obtaining a curcuminoid; obtaining a peptide; and mixing the curcuminoid and the peptide in a solvent. Also disclosed are methods of treating a subject, the method comprising identifying a subject in need of treatment of a curcumin-related disorder, and administering to the subject a therapeutic composition comprising a curcuminoid-peptide complex as described. Also disclosed are therapeutic compositions comprising a curcuminoid-peptide complex as described and a pharmaceutically acceptable excipient, diluent, or carrier.

Abstract: Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease.

Abstract: In certain aspects, the present invention provides compositions and methods for inducing utrophin expression in muscle with an ActRIIB protein as therapy for muscular dystrophy. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand.

Abstract: Problems to be Solved The present invention provides an affinity support capable of trapping a substance by cooperative binding that is less likely to cause dissociation even when the substance is a molecule other than an antibody, and a trapping method using the same. Means to Solve the Problems A method of trapping a substance comprising the step of contacting an objective to be trapped with an affinity support comprising a support, a spacer bound to the support and an affinity substance bound to the spacer, so as to bind the objective to be trapped to the affinity substance, wherein each one of the objective to be trapped has a plural of affinity sites and the affinity substance binds to at least two of the affinity sites simultaneously.

Abstract: The present invention comprises compounds of Formula I. wherein: Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.

Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.

Abstract: Provided herein are glucose-dependent insulinotropic polypeptide (GIP)-derived peptide analogues, for example GIP(3-30), and their use as antagonists of the GIP receptor and for treatment of disorders such as obesity, diabetes mellitus and insulin resistance.

Abstract: Disclosed is a medicine containing a long-lasting human growth hormone preparation as an active ingredient, which has low prolactin-like activity and shows long half-life in blood as compared with 22K human growth hormone. The long-lasting human growth hormone includes a fusion protein exhibiting growth-promoting activity and having a human serum albumin part and a 20K human growth hormone part, particularly a fusion protein in which the 20K human growth hormone part is linked to C-terminus of the human serum albumin part via a linker sequence.

Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.

Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules containing one or more Borrelia derived peptides are disclosed. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the sample-mounted use of MHC complexes and MHC multimers. Also comprised by the invention is the field of therapy and vaccine, including therapeutic/vaccine methods and therapeutic/vaccine compositions.

Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.

Abstract: The present invention relates to amino acid sequences that are directed against Interleukin-23 (IL-23). The amino acid sequences of the present invention comprise two NANOBODIES® against IL-23 and one NANOBODY® against serum albumin, linked by two linkers (9GS linkers). In particular, the invention relates to the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3 (listed in Table 1 and FIG. 1) (also referred to herein as “anti-IL 23 polypeptides of the invention”).

Abstract: This invention relates to a novel use of IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.

Abstract: Provided is an anti-INF-? antibody. Also provided are a composition comprising the antibody and a pharmaceutical application of the antibody in treating IFN-? mediated syndrome.

Abstract: The present disclosure relates to anti-ROR1 binding proteins, including those that bind to a ROR1 or portion thereof such as an intracellular C terminal portion of a ROR1 protein, and the use of such binding proteins in immunohistochemical and diagnostic methods. Related kits and methods of using the binding proteins are also provided, as are methods of treatment of subjects having diseases or conditions determined to be candidates for such treatments by the binding proteins or methods of this disclosure.

Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.

Abstract: Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.

Abstract: The present invention provides compositions and methods of treating and improving the symptoms of uveitis and/or macular edema using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).

Abstract: Disclosed are antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described.

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

Abstract: The present invention provides a new anti-LSP1 (Leukocyte specific protein 1) antibody. This new antibody allows the specific staining of inflammatory dendritic cells and can be used in diagnosis methods or as a medicament when conjugated to a drug.

Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.

Abstract: A method for producing functionalized nanocrystalline cellulose, the method comprising the steps of providing cellulose, mixing said cellulose with a peroxide, thereby producing a reaction mixture, and heating the reaction mixture, and/or exposing the reaction mixture to UV radiation is provided. Functionalized nanocrystalline cellulose produced by this method is also provided.

Abstract: The present invention is a multilayered composite comprising porous metal oxide particles that are covalently bonded by way of inorganic ether groups to one or more sites of a first polyhydroxyl-functionalized polymer. This first polymer is in turn covalently bonded by way of inorganic ether groups to one or more sites of a second polyhydroxyl-functionalized polymer. The multilayered composites can be prepared by contacting porous inorganic-oxide particles with a sufficient amount of OH-reactive crosslinking agent to form metal oxide particles imbibed with the crosslinking agent, and then contacting the inorganic-oxide particles with a solution of polyhydroxyl-functionalized polymer under reactive conditions.

Abstract: The present invention discloses a matrix comprising a modified polysaccharide consisting of repeating disaccharide units whereby in at least 11% of the disaccharide units one primary alcohol group is oxidized into a carboxylic acid group.

Abstract: The present invention relates to site-selective modification of polysaccharides at their reducing end by conjugation with a single aminoxy-Regioselective Addressable Functionalized Template (RAFT) peptide.

Abstract: A method for producing a hydrogenated conjugated diene polymer latex includes: a hydrogenation step of dissolving or dispersing a hydrogenation catalyst containing a platinum group element in a latex of a conjugated diene polymer to hydrogenate a carbon-carbon unsaturated bond in the polymer; an insoluble complex formation step of complexing the platinum group element with a complexing agent to form an insoluble complex; and an insoluble complex removing step of continuously feeding the latex which has undergone the insoluble complex formation step to a centrifuge machine and continuously performing a centrifugation operation to continuously remove the insoluble complex from the latex and continuously discharge the insoluble complex out of the centrifuge machine. In the insoluble complex removal step the feed rate of the latex to the centrifuge machine is adjusted to 0.5 to 15 m3/hour, and the centrifugal force in the centrifugation operation is adjusted to 200 to 10,000 G.

Abstract: A method of forming a coating on a food or beverage container, which includes spraying a coating composition onto an interior surface of the food or beverage container, where the coating composition includes an emulsion-polymerized latex copolymer having copolymer chains of one or more ethylenically-unsaturated monomers and one or more styrene offset monomers. Preferably, the coating composition is substantially free of BPA, PVC, and styrene. The method may also include curing the sprayed coating composition, thereby providing the coating on the interior surface of the food or beverage container.

Abstract: Olefin polymerization catalyst systems are provided that include a procatalyst component having a metal-ligand complex of Formula (I): [formula] (I) where each X is a neutral, monoanionic, or dianionic, monodentate or polydentate ligand such that the complex of Formula (I) is neutral; each R1 and R10 is a (C6-C40)aryl, substituted (C6-C40)aryl, (C3-C40)heteroaryl, or substituted (C3-C40)heteroaryl; each R2, R3, R4, R7, R8, and R9 is a hydrogen; (C1-C40)hydrocarbyl; substituted (C1-C40)hydrocarbyl; (C1-C40)heterohydrocarbyl; substituted (C1-C40)heterohydrocarbyl; halogen; or nitro (NO2) group; and each R5 and R6 is a (C1-C)alkyl; substituted (C1-C40)alkyl; or [(Si)1—(C+Si)40] substituted organosilyl. Additionally, olefin-based polymers and processes for polymerizing one or more olefin-based polymers in the presence of the olefin polymerization catalyst systems are also provided.

Abstract: Unsaturated and hydrogenated polyalpha-olefin products can be made with a high selectivity toward vinylidenes and tri-substituted vinylenes combined, a high selectivity toward vinylidenes, and a low selectivity toward 1,2-di-substituted vinylenes by using a catalyst system comprising a metallocene compound having the following structure in the polymerization reaction:

Abstract: A process for preparing an ethylene polymer including the step of homopolymerizing ethylene or copolymerizing ethylene with one or more comonomers in a gas-phase polymerization reactor including a riser unit wherein growing polymer particles flow upwards under fluidization, fast fluidization or transport conditions and a downcomer wherein growing polymer particles flow downward in a densified form, wherein the hold-up of polymer particles in the downcomer is from 55 wt. % to 80 wt. % of the total hold-up of polymer particles in the gas-phase polymerization reactor.

Abstract: A synthetic polymer film is a synthetic polymer film whose surface has a plurality of raised or recessed portions. The synthetic polymer film has a crosslink structure, and the crosslink structure does not contain any nitrogen element that is a constituent of a urethane bond. The synthetic polymer film contains an organic carboxylic acid, and an amount of water required for dissolving 1 g of the organic carboxylic acid is equal to or greater than 10 mL and less than 10000 mL. At the lapse of 5 minutes since placing a 200 ?L drop of water on the surface of the synthetic polymer film, a pH of an aqueous solution is not more than 5, and an area equivalent circle diameter of the aqueous solution is not less than 20 mm. A synthetic polymer film whose surface has a microbicidal activity can be produced using a photocurable resin composition which contains an organic carboxylic acid or a photoacid generator which generates the organic carboxylic acid.

Abstract: Process for preparing an olefin polymer including the step of polymerizing an olefin in the presence of a polymerization catalyst and hydrogen as molecular weight regulator in a gas-phase polymerization reactor to yield growing polymer particles, the reactor including three or more polymerization zones and at least two thereof are sub-zones of a polymerization unit wherein the growing polymer particles flow downward in a densified form and at least one polymerization zone has a ratio of hydrogen to the sum of olefins which is a factor of at least 1.5 lower than the ratio of hydrogen to the sum of olefins in the polymerization zone having the highest ratio of hydrogen to the sum of olefins and a factor of at least 1.5 higher than the ratio of hydrogen to the sum of olefins in the polymerization zone having the lowest ratio of hydrogen to the sum of olefins.

Abstract: The present invention relates to a process for preparing high-reactivity isobutene homo- or copolymers with a content of terminal vinylidene double bonds per homo- or copolymer chain end of at least 70 mol % which comprises polymerizing isobutene or an isobutene-comprising monomer mixture in the presence of an aluminum trihalide-donor complex effective as a polymerization catalyst or of an alkylaluminum halide-donor complex, said complex comprising, as the donor, a mixture of at least two organic compounds with at least one ether function each.

Abstract: An acrylic acid polymer having a weight average molecular weight Mw in the range from 3500 to 2000 g/mol and a polydispersity index Mw/Mn?2.5, wherein 30% to 60% of the acid groups of the acrylic acid polymers have been neutralized with calcium ions, 30% to 70% of the acrylic acid polymers have been neutralized with sodium ions and 0% to 10% of the acid groups of the acrylic acid polymers have not been neutralized.

Abstract: The invention relates to the use of low levels of aliphatic primary and secondary amines to control air void formation in any polymerization reaction having carbonyl groups, and especially carboxylic acid ester group-containing monomers at a level of at least 10% of total monomer, where the monomer has a peak polymerization exotherm temperature of greater than the boiling point of the monomer. The primary or secondary amines are used in the polymerization mixture at levels of 100 to 5000 ppm, based on the carboxylic acid ester group-containing monomer. It is believed the primary and secondary amines hydrogen bond with the —C?O)O— containing monomer to increase the monomer boiling point, and decrease or even eliminate the formation of air voids due to monomer boiling. The invention is especially useful in polymerization of methymethacrylate polymers and copolymers, either neat, or as a polymer composite system.

Abstract: Catalyst compositions and polymerization systems include at least one thiourea complex according to Formula (I): MQaX4-a (I) in which M is Ti, Zr, or Hf; a is 1 or 2; each group Q of the thiourea complex is a bidentate thiourea ligand bound to the metal center and having Formula (Ia), Formula (Ib), or Formula (Ic): (Formulas should be inserted here). In Formulas (Ia), (Ib), and (Ic), each group R1, R2, and R3 is independently chosen from alkyl groups or aryl groups; each group Z1 or Z2 is independently chosen from alkylene groups. If a=2, groups R1 of the two groups Q are optionally linked, or groups R3 of the two groups Q are optionally linked. Each X is covalently bonded or coordinated to the metal center and is independently chosen from alkyl groups or halides. The polymerization systems may be configured to copolymerize ethylene and ?-olefins.

Abstract: Disclosed are aqueous emulsion copolymerization processes for synthesizing 2,3,3,3-tetrafluoropropene/vinylidene fluoride copolymers having 2,3,3,3-tetrafluoropropene as the major monomer unit. The copolymerization process is performed at temperatures of from about 55° C. to about 70° C. with at least one water soluble radical initiator, with preferred initiators including Na2S2O8, K2S2O8, (NH4)2S2O8, Fe2(S2O8)3, K2S2O8/FeSO4, (NH4)2S2O8/Fe2O4, and the like, as well as combinations thereof.

Abstract: The present invention is a copolymer containing, as essential structural units, unit A represented by Formula (1) and unit B represented by Formula (2): (wherein R1 and R4 each independently represent a hydrogen atom or a methyl group, and R2 and R3 each independently represent a hydrogen atom or a C1-20 hydrocarbon group, excluding cases where two or more groups of R1 to R3 are hydrogen atoms.) (wherein R5 represents a hydrogen atom or a methyl group, and R6 represents a group selected from the group consisting of C1-20 hydrocarbon groups optionally containing an oxygen atom, C1-20 alkoxy groups, hydrogen atoms, oxygen radicals and hydroxyl groups.

Abstract: A method of increasing a polymerization reaction rate of a base monomer composition that has slow free-radical polymerization kinetics. The method comprises combining an effective amount of a nanogel to the base monomer composition to form a monomer-nanogel mixture having a polymerization reaction rate that is greater than the polymerization reaction rate of the base monomer composition when subjected to an identical free-radical polymerization reaction conducted under identical conditions. The base monomer composition comprises one or more slow-kinetic monomers with slow free radical polymerization kinetics in which <25% of the double bonds are converted within the first 10 mintes of said reaction. The nanogel is soluble in the base monomer composition. The nanogel is derived from a nanogel-forming monomer mixture that comprises: at least one monovinyl monomer; at least one divinyl monomer; a chain transfer agent; and an initiator.